Telo Genomics Corp.

Telo Genomics Announces Successful Validation of Its Proprietary Automation Tools for Smoldering Multiple Myeloma

Toronto, Ontario--(Newsfile Corp. - May 31, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") announces that it has completed the validation of a suite of proprietary automation tools developed using cutting-edge machine learning, deep machine learning and artificial intelligence technologies to maximize the efficiency and throughput of its technology workflow. The validation was conducted on a subset of smoldering multiple myeloma (SMM) patient samples that...

2022-05-31 8:45 AM EDT

Telo Genomics Announces Investor Relations Agreement and Option Grants

Toronto, Ontario--(Newsfile Corp. - March 15, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce that it has engaged Tracey Kidd ("Kidd") to perform services related to investor relations activities for the Company, as defined in accordance with the polices of the TSX Venture Exchange ("TSXV") and applicable securities laws. Pursuant to an engagement agreement entered into with Kidd on March 15, 2022 (the "Engagement Agreement"), Kidd will...

2022-03-15 8:45 AM EDT

Telo Genomics Launches Clinical Validation of its Smoldering Multiple Myeloma Diagnostic Test

Toronto, Ontario--(Newsfile Corp. - March 7, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3D0A) (the "Company" or "TELO") announces that it has received clinical samples from its collaborator, Mayo Clinic, to conduct the clinical validation of the Company's lead product in development, its TeloView® prognostic test for segregating high risk and low risk smoldering multiple myeloma (SMM) patients. TELO announced on March 28, 2021, that it had completed the feasibility stage of...

2022-03-07 8:45 AM EST

Telo Genomics Appoints Dr. McGlennen as Board Director, a Leader in Commercializing Novel Diagnostic Technologies

Toronto, Ontario--(Newsfile Corp. - February 3, 2022) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to announce that Dr. Ron McGlennen, President and Founder of the medical laboratory Access Genetics, Minnesota, USA, has joined its Board of Directors. Dr. McGlennen brings unique and valuable expertise to TELO's board with extensive experience in successfully introducing novel diagnostics technologies into clinical laboratories across the USA. Dr. McGlennen brings...

2022-02-03 8:51 AM EST

Telo Genomics Advances Its Lead Product and Implements Automation to Its Workflow

Toronto, Ontario--(Newsfile Corp. - January 19, 2022) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") announces the launch of a validation study to accelerate the commercialization of its lead product in development for smoldering multiple myeloma (SMM) patients. The Company also announces that it has recently implemented in its workflow several proprietary automation solutions that employed cutting edge machine learning and artificial intelligence algorithms. TELO has recently...

2022-01-19 8:55 AM EST

Telo Genomics Announces OTCQB Venture Market Listing

Toronto, Ontario--(Newsfile Corp. - December 7, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to announce its successful uplisting from the OTC Pink Sheets to the OTCQB® Venture Market (the "OTCQB"). TELO commenced trading on the OTCQB at market open on December 06, 2021 under the symbol "TDSGF". TELO common shares will continue to trade on the Toronto Venture Exchange under the symbol TELO. The OTCQB Venture Market, operated by OTC Markets Group Inc., is...

2021-12-07 1:24 PM EST

Telo Genomics Announces the Outcome of its Participation in the International Myeloma Workshop and Clinical Studies Progress

Toronto, Ontario--(Newsfile Corp. - October 13, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to announce updates related to its recent participation in the International Multiple Myeloma Workshop in Vienna, Austria, and progress of the ongoing clinical studies in collaboration with the Mayo Clinic. TELO has recently participated in the International Myeloma Workshop (IMW 2021) that took place in Vienna, Austria. During the IMW 2021 TELO held important meetings...

2021-10-13 8:30 AM EDT

Telo Genomics Adopts Advanced Notice Provisions in By-Laws

Toronto, Ontario--(Newsfile Corp. - October 5, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to announces its board of directors (the "Board") has adopted amendments to its By-Laws (the "Amended By-Laws") to include advance notice provisions (the "Advance Notice Provisions") which require shareholders of the Company ("Shareholders") to provide advance notice to the Company when nominating persons for election to the Board. The Advance Notice Provisions provide...

2021-10-05 8:30 AM EDT

Telo Genomics Announces Full-Services Investor Relations Agreement with Adelaide Capital

Toronto, Ontario--(Newsfile Corp. - September 21, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to announce that it has entered into a consulting agreement (the "Consulting Agreement") with Adelaide Capital Markets Inc. ("Adelaide") to provide investor relations consulting services to the Company in compliance with the policies and guidelines of the TSX Venture Exchange (the "TSXV") and applicable legislation. Adelaide will provide investor relations and...

2021-09-21 8:45 AM EDT

Telo Genomics Participates in the 18th International Myeloma Society Workshop 2021

Toronto, Ontario--(Newsfile Corp. - September 9, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to announce that it is participating in the 18th International Myeloma Society Workshop 2021 (IMW 2021) taking place in Vienna, Austria between September 8th - 11th. Telo Genomics will showcase the clinical utility and unique advantages of its TeloView® technology, and its potential as a transformative liquid biopsy prognostics solution for managing multiple myeloma....

2021-09-09 8:30 AM EDT

Telo Genomics Engages Clinical and Regulatory Affairs Veteran to Lead the Company's ISO 15189 Certification & CLIA Laboratory Accreditation Undertaking

Toronto, Ontario--(Newsfile Corp. - August 9, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to announce that the Company has entered into an agreement with the clinical laboratory veteran Mark Stene, Founder & President of MyClinLab® LLC, Austin, Texas USA. Mark Stene is a former senior executive with several clinical laboratories and medical device enterprises in the USA. Dr. Stene brings a record of accomplishment in guiding biotech companies through the...

2021-08-09 8:30 AM EDT

Telo Genomics Completes Final Tranche of Oversubscribed Private Placement

Toronto, Ontario--(Newsfile Corp. - July 5, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") announces that it has closed the second and final tranche of its previously announced non-brokered private placement ("Offering") of units (the "Units") and issued an additional 390,000 Units for gross proceeds of $195,000. The originally announced Offering was oversubscribed and along with the first tranche of the Offering, the Company has now raised $2,287,750. Each Unit issued...

2021-07-05 8:45 AM EDT

Telo Genomics Completes First Tranche of Oversubscribed Private Placement

Toronto, Ontario--(Newsfile Corp. - July 2, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") announces that it has closed the first tranche of its previously announced non-brokered private placement ("Offering") of units (the "Units"). The Company issued a total of 4,185,500 Units at a price of $0.50 per Unit for gross proceeds of $2,092,750 under the first tranche of the Offering. Each Unit issued consisted of one common share of the Company (a "Common Share") and one-half...

2021-07-02 8:45 AM EDT

Telo Genomics Announces Private Placement of Units

Toronto, Ontario--(Newsfile Corp. - June 18, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to announce a non-brokered private placement of units ("Units") at a price of $0.50 per Unit for gross proceeds of $1,500,000 (the "Offering"). Each Unit will consist of one common share of the Company (a "Common Share") and one-half of one non-transferable common share purchase warrant (each whole warrant, a "Warrant"). Each Warrant will entitle the holder to acquire one...

2021-06-18 10:00 AM EDT

Telo Genomics Announces Co-Authored Publication of a Prospective 5-year Multiple Myeloma Study - Successfully Identifying High Risk versus Low Risk Smoldering Myeloma Patients

Toronto, Ontario--(Newsfile Corp. - April 29, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to announce that it has co-authored a publication demonstrating TELO's ability to identify high risk versus low-risk smoldering myeloma patients in a large longitudinal prospective multiple myeloma clinical study including 214 patients. The study was recently published in the Scientific Journal titled "Cancers". "This study confirms the potential of TeloView® technology...

2021-04-29 8:30 AM EDT

Telo Genomics Announces AGM Voting Results and Provides Corporate Update

Toronto, Ontario--(Newsfile Corp. - March 24, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to announce the results of its recent annual general shareholders meeting (the AGM) held on March 04, 2021 in Toronto, ON. The Company is also pleased to provide a corporate update, including an update on its lead clinical development program. AGM Results TELO wishes to announce the voting results from the AGM held on March 04, 2021. A total of 5,161,568 shares...

2021-03-24 9:15 AM EDT

Recent News